NBTX
HEALTHCARENanobiotix
$41.86+7.09 (+20.39%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving NBTX Today?
No stock-specific AI insight has been generated for NBTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.33$44.46
$41.86
Fundamentals
Market Cap$2.0B
P/E Ratio—
EPS$-0.59
Dividend Yield—
Dividend / Share—
ROE-2.0%
Profit Margin-0.7%
Debt / Equity—
Trading
Volume128K
Avg Volume (10D)—
Shares Outstanding48.5M
NBTX News
22 articles- Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer StudyYahoo Finance·May 4, 2026
- Assessing Nanobiotix (ENXTPA:NANO) Valuation After Strong Recent Share Price MomentumYahoo Finance·Apr 27, 2026
- Nanobiotix annonce de nouvelles données précliniques démontrant une amélioration de la biodisponibilité systémique et la réduction de la toxicité pour des immunothérapies à ADN delivrées par LNP après traitement avec sa technologie de nanoprimerGlobeNewswire Inc.·Apr 20, 2026
- Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer TechnologyGlobeNewswire Inc.·Apr 20, 2026
- Voting Rights and Shares Capital of the CompanyYahoo Finance·Apr 7, 2026
- Nanobiotix H2 Earnings Call HighlightsMarketbeat·Apr 1, 2026
- NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial ResultsYahoo Finance·Mar 31, 2026
- NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung CancerYahoo Finance·Mar 30, 2026
- NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026Yahoo Finance·Mar 26, 2026
- Sector Update: Health Care Stocks Gain Late AfternoonYahoo Finance·Mar 25, 2026
- Cancer Drug Developer Nanobiotix Denies Any Active Takeover ProcessBenzinga·Mar 25, 2026
- NANOBIOTIX Statement Regarding Recent Media SpeculationBenzinga·Mar 25, 2026
- NANOBIOTIX to Participate in Investor Conferences in MarchYahoo Finance·Feb 25, 2026
- NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext ParisYahoo Finance·Dec 15, 2025
- Nanobiotix (ENXTPA:NANO): Assessing Valuation After a Powerful Multi‑Month Share Price SurgeYahoo Finance·Dec 8, 2025
- Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical OutlookYahoo Finance·Nov 24, 2025
- Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could ContinueMotley Fool·Nov 24, 2025
- Soft Tissue Sarcoma Market Analysis Report 2025-2035, Profiles of Novartis, Nanobiotix, Adaptimmune, and Ipsen PharmaYahoo Finance·Nov 19, 2025
- NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External CollaborationsYahoo Finance·Nov 13, 2025
- Nanobiotix (ENXTPA:NANO): Evaluating Valuation After $71 Million Royalty Deal Expands Growth ProspectsYahoo Finance·Nov 13, 2025
- Why Nanobiotix (ENXTPA:NANO) Is Up 5.9% After Securing $71M in Non-Dilutive Financing and What’s NextYahoo Finance·Nov 13, 2025
- NANOBIOTIX to Participate in Jefferies London Healthcare ConferenceYahoo Finance·Nov 11, 2025
All 22 articles loaded
Price Data
Open$0.00
Previous Close$34.77
Day High$0.00
Day Low$0.00
52 Week High$44.46
52 Week Low$3.33
52-Week Range
$3.33$44.46
$41.86
Fundamentals
Market Cap$2.0B
P/E Ratio—
EPS$-0.59
Dividend Yield—
Dividend / Share—
ROE-2.0%
Profit Margin-0.7%
Debt / Equity—
Trading
Volume128K
Avg Volume (10D)—
Shares Outstanding48.5M
About Nanobiotix
Nanobiotix SA, a clinical-stage biotechnology, is focused on the development of candidate products for the treatment of cancer. The company is headquartered in Paris, France.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—